TOP TEN perturbations for 1553265_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1553265_at
Selected probe(set): 230949_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1553265_at (230949_at) across 6537 perturbations tested by GENEVESTIGATOR:
nephroblastoma study 2 / normal kidney tissue
Relative Expression (log2-ratio):-3.3598385Number of Samples:4 / 3
Experimental | nephroblastoma study 2 |
Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
Control | normal kidney tissue |
Normal adult kidney tissue samples. |
autosomal dominant polycystic kidney disease study 1 (cystic tissue) / non-tumor kidney tissue
Relative Expression (log2-ratio):-3.3425264Number of Samples:4 / 3
Experimental | autosomal dominant polycystic kidney disease study 1 (cystic tissue) |
Cystic tissue samples from patients with autosomal dominant polycystic kidney disease (ADPKD). Tissue was derived after nephrectomy from renal cortices containing microscopic small cysts. | |
Control | non-tumor kidney tissue |
Histologically normal renal cortex tissue samples from nephrectomized kidneys from patients with isolated renal cell carcinoma. |
collecting duct carcinoma study 1 / normal kidney tissue
Relative Expression (log2-ratio):-3.1962013Number of Samples:2 / 3
Experimental | collecting duct carcinoma study 1 |
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC). | |
Control | normal kidney tissue |
Normal adult kidney tissue samples. |
oxyphilic adenoma study 1 / normal kidney tissue
Relative Expression (log2-ratio):-3.0445156Number of Samples:4 / 3
Experimental | oxyphilic adenoma study 1 |
Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma). | |
Control | normal kidney tissue |
Normal adult kidney tissue samples. |
renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue
Relative Expression (log2-ratio):-3.0295315Number of Samples:4 / 3
Experimental | renal cell carcinoma study 6 (chromophobe type) |
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC). | |
Control | normal kidney tissue |
Normal adult kidney tissue samples. |
renal cell carcinoma study 5 (papillary type) / normal kidney tissue
Relative Expression (log2-ratio):-2.9342813Number of Samples:19 / 3
Experimental | renal cell carcinoma study 5 (papillary type) |
Tumor tissue samples from the kidney of patients with papillary renal cell carcinoma (pRCC). | |
Control | normal kidney tissue |
Normal adult kidney tissue samples. |
PMA study 6 (500ng/ml) / vehicle (DME) treated bronchial epithelial cell sample
Relative Expression (log2-ratio):2.56744Number of Samples:3 / 17
Experimental | PMA study 6 (500ng/ml) |
Bronchial epithelial cells (NHBE) treated with tetradecanoylphorbol acetate (500ng/ml; vendor: Sigma / catalog number: P1585 / catalog name: Phorbol 12-myristate 13-acetate [16561-29-8]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:--- | |
Control | vehicle (DME) treated bronchial epithelial cell sample |
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). |
ulcerative colitis study 9 (prior therapy) / normal colon tissue
Relative Expression (log2-ratio):-2.4121618Number of Samples:8 / 11
Experimental | ulcerative colitis study 9 (prior therapy) |
Colon biopsies derived from pediatric patients diagnosed with ulcerative colitis at time of enrollment. Patients were not receiving medications for the treatment of inflammatory bowel disease at the time the biopsy was taken. | |
Control | normal colon tissue |
Colon biopsies derived from pediatric healthy controls. |
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-2.324132Number of Samples:3 / 3
Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
kidney transplantation study 41 (AR) / kidney transplantation study 41 (stable)
Relative Expression (log2-ratio):-2.252163Number of Samples:14 / 18
Experimental | kidney transplantation study 41 (AR) |
Renal allograft biopsies from pediatric patients with acute rejection (AR). The diagnosis of AR was confirmed by a pathologist. All patients were under the same double (Tacrolimus and MMF) or triple immunosuppression protocols (Tacrolimus, MMF and steroid), and all had received Daclizumab induction therapy. None of patients was infected with BK virus. | |
Control | kidney transplantation study 41 (stable) |
Renal allograft biopsies from pediatric patients with stable graft function. Samples were taken during the regular post-transplantation follow-up. All patients were under the same double (Tacrolimus and MMF) or triple immunosuppression protocols (Tacrolimus, MMF and steroid), and all had received Daclizumab induction therapy. None of patients was infected with BK virus. Further patients’ characteristics: mean age 11.7 ± 5.5 years (age range 1-19 years), steroid-free drug treatment 33%, sample collection time 9.3 ± 6.1 months post-transplant (range 2-25 months post-transplant), end-stage renal disease (ESRD): 17% glomerulonephritis, 12% polycystic kidney disease, 18 % dysplasia, 6% obstructive uropathy, 47% other. |